IL6 and cancer: As shown in Figure 10, we found that the best combination of circulating biomarkers to predict R (DFS ≥ 1 year) and NR (DFS < 1 year) patients in our cohort of metastases-resected cancer patients was represented by 3-hydroxybutyrate, cholesterol, phospholipids, triglycerides and IL-6, evaluated in plasma samples collected at the time of the response evaluation.